@article{b487d78f099648968a2e996baf2129dd,
title = "Losartan versus atenolol-based antihypertensive treatment reduces cardiovascular events especially well in elderly patients: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study",
abstract = "The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study has previously demonstrated a beneficial effect of losartan compared to atenolol-based antihypertensive treatment in patients with essential hypertension and left-ventricular hypertrophy (LVH). However, patient age often influences the choice of antihypertensive drugs. Therefore, we investigated the influence of age on the effects of losartan versus atenolol-based antihypertensive treatment.",
keywords = "Adrenergic beta-1 Receptor Antagonists, Aged, Aged, 80 and over, Angiotensin II Type 1 Receptor Blockers, Antihypertensive Agents, Atenolol, Blood Pressure, Cardiovascular Diseases, Double-Blind Method, Female, Humans, Losartan, Male, Middle Aged, Risk Factors",
author = "Ruwald, {Anne Christine H} and Bo Westergaard and Thomas Sehestedt and Kjeldsen, {Sverre E} and Lindholm, {Lars H} and Kristian Wachtell and Devereux, {Richard B} and Hans Ibsen and Nieminen, {Markku S} and Bj{\"o}rn Dahl{\"o}f and Olsen, {Michael H}",
year = "2012",
doi = "10.1097/HJH.0b013e328352f7f6",
language = "English",
volume = "30",
pages = "1252--9",
journal = "Journal of Hypertension",
issn = "0263-6352",
publisher = "Lippincott Williams & Wilkins, Ltd",
number = "6",
}